Nuochengjianhua announced on November 6 that three studies of the novel BCL2 inhibitor Metocla independently developed by the company were selected for the 68th Annual Meeting of the American Hematology Association. Metocla's study on the treatment of myelodysplastic syndrome was selected as an oral report at this ASH annual conference. At the same time, research on the treatment of acute myeloid leukemia and B-cell malignancies by Metocla was selected for the poster presentation at this year's ASH annual conference, respectively.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.